|
|
Distinguished
Presenters and Panelists: |
 |
Michael D. Blum, M.D.,
M.P.H., Vice President, Global Safety Surveillance and Epidemiology,
Wyeth Research |
.jpg) |
J. David Haddox, DDS, M.D., Vice President, Risk Management & Health Policy,
Purdue Pharma L.P. Purdue Pharma L.P. |
 |
Daniel K. Burns, Ph.D., Senior Vice President, Therapeutic Matrix, Compliance and Pharmacovigi-lance,
GlaxoSmithKline |
 |
Alexander Ommaya, Sc.D., Director, Translational Research, Office of Research and Development,
US Department of Veterans Affairs |
.jpg) |
Vikram Dev, M.D., Vice
President, Head of Drug Safety,
AstraZeneca |
.jpg) |
Judith M. Sills, PharmD, Vice President and Head, Medical Safety Operations, Integrated Medical Safety,
Novartis Pharmaceuticals |
.jpg) |
John Ferguson, M.D., Vice President, Pharmacovigilance,
Millennium Pharmaceuticals, Inc. |
.jpg) |
Sean Zhao, M.D., Ph.D., Executive Director, Global Safety,
Amgen, Inc. |
| |
Carmen Castaneda, M.D., Senior Medical Reviewer, Worldwide Drug Safety,
Celgene Corporation |
|
Uwe Maennl, Vice President and Global Head Pharmacovigilance,
PAREXEL |
| |
Patrick M. Caubel, M.D., MBA, AVP, Head of Pharmacovigilance North America,
sanofi-pasteur |
|
Joanna L. C. May, Business Alliance Consultant, Global Product Safety,
Eli Lilly and Company |
| |
Donald B. Chalfin, M.D., Associate Professor of Epidemiology,
Albert Einstein College of Medicine and Chief Scientific Officer,
Analytica International |
|
Peggy Schrammel, Executive Director, Late Phase Development,
PharmaNet |
| |
Fran Cunningham, PharmD, Director, Center for Medication Safety, Veterans Health Administration,
US Department of Veterans Affairs |
|
Eleanor S. Segal, M.D., Vice President and Head, Global Drug Safety,
Actelion Pharmaceuticals Ltd. |
| |
Gerald Faich, M.D., MPH, FISPE, Senior Vice President, Epidemiology and Risk Management,
United Bio-Source Corporation |
|
Robert G. Sharrar, M.D., M.Sc., Executive Director, Clinical Risk Management & Safety Surveillance,
Merck & Co., Inc. |
| |
Alan Goldberg, R.Ph., Director, Drug Safety Services, Periapproval,
Covance, Inc. |
|
Annette Stemhagen, DrPH, FISPE, Vice President, Epidemiology and Risk Management,
United BioSource Corporation |
| |
Nilima Justice, M.D., Senior Director Product Safety Surveillance,
Novo Nordisk, Inc. |
|
Jan Willem van der Velden, M.D., Senior Vice President, Global Safety and Pharmacovigilance,
PharmaNet |
| |
Vivek Kadambi, Director, Drug Safety Evaluation,
Millennium Pharmaceuticals, Inc. |
|
|
Presentations, In-Depth Case
Studies, and Interactive Panels
- Integrating drug safety knowledge across a compounds lifecycle
- Structured benefit-risk balance:
Update on industry initiatives
- Risk management in early development: The preclinical/clinical safety feedback loop
- Decreasing liability and improving brand by employing a proactive communication and risk management strategy
- The other side of the benefit-risk
ratio: Outcomes research as a means of demonstrating product benefit
- Leveraging drug registry tools to assess safety and performance
- Embracing the shifting paradigm from post- to pre-approval safety
Inclusive Pre-Conference Case
Study-Based Workshop:
Identifying and Managing
Pharmacovigilance Risk with a Business Partner |
|
|
